Advancing Digital Oncology Through Public-Private Partnerships

We have made remarkable progress in oncology treatments, yet, many patients are still grappling with basic, and often preventable, barriers to care.

This is why CancerX was formed.

CancerX is a public-private partnership announced by The White House as a national accelerator to drive cancer care innovation, as part of the reignited Cancer Moonshot. Led by the Moffitt Cancer Center and the Digital Medicine Society (DiMe), CancerX has united over 90 founding members to leverage the power of digital innovation and dismantle these barriers.

With collaboration at its heart, CancerX seeks to gather a broad spectrum of stakeholders, aiming to alleviate the cancer burden universally. This initiative champions high-quality innovation in oncology, filling methodological voids, and establishing best practices for equitable implementation. This approach paves the way for the application of digital innovation across the entire care continuum, accelerating the creation of transformative solutions for cancer patients, providers, and researchers. In fact, CancerX sets an ambitious goal — to reduce cancer deaths by 50% by 2047.

The value of collaboration realised through public-private partnerships, such as CancerX, is evident,  but what are the implications for the wider healthcare industry? Join our roundtable discussion to explore:

• The Goals of CancerX. What are the objectives of this initiative and who is leading it?
• The CancerX Approach. What does CancerX's three-pronged approach entail for stakeholders in the oncology ecosystem?
• The Impact of Public-Private Partnerships. How can we anticipate the impact of public-private partnerships across the healthcare landscape?